Overview

FRDA Investigator Initiated Study (IIS) With Elamipretide

Status:
Not yet recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, and activity of Elamipretide in treating vision loss in Friedreich Ataxia (FRDA).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Children's Hospital of Philadelphia
Collaborators:
Friedreich's Ataxia Research Alliance
Stealth BioTherapeutics Inc.